Inactive Instrument

Press Releases Protagonist Therapeutics Inc Nasdaq

Equities

US74366E1029

End-of-day quote Nasdaq Other stock markets
- ^PTS	-

07-03	Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 1000	CI
07-03	Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 600 Health Care	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024	06-28	AQ
Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control	06-17	AQ
Protagonist Therapeutics: Q1 Earnings Snapshot	05-07	AQ
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data	03-27	AQ
Protagonist Therapeutics: Q4 Earnings Snapshot	02-27	AQ
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024	01-30	AQ
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals	12-13	AQ
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib	11-28	AQ
Protagonist Therapeutics: Q3 Earnings Snapshot	11-02	AQ
Protagonist Announces Advancement of JNJ-2113 across Multiple Indications	23-10-10	AQ
Protagonist Therapeutics to Present at Upcoming Investor Conferences	23-09-06	AQ
Protagonist Receives $34 Million from Warrant Exercises	23-08-10	AQ
Protagonist Therapeutics Reports Granting of Inducement Award	23-07-19	AQ
Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113	23-05-15	AQ
Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113	23-05-12	PR
Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference	23-05-11	PR
Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association	23-05-11	PR
Protagonist Therapeutics: Q1 Earnings Snapshot	23-05-04	AQ
PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	23-05-04	AQ
PROTAGONIST THERAPEUTICS, INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	23-05-04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Protagonist Therapeutics Inc Nasdaq

Equities

US74366E1029

Press Releases

Filters